Green Cross (006280), a leading biopharmaceutical firm, has laid a robust groundwork for sustained expansion in the U.S. market through its innovative blood product Alyglo, as highlighted by Heungkuk Securities analysts on May 19. This positions the company to capture significant share in the booming intravenous immunoglobulin (IVIG) sector, addressing rising demand for treatments in immunodeficiencies and autoimmune disorders amid an aging global population.
Alyglo's Ambitious Market Targets and Early Momentum
At its recent Investor Day, Green Cross outlined a mid-to-long-term goal of 10% U.S. market share for Alyglo, translating to roughly $650 million in annual sales. Analysts project 2025 sales at $106 million, or 1.6% share, with high growth fueled by expanding prescriptions and robust global IVIG demand, which exceeds supply due to chronic conditions like primary immunodeficiencies and neurological diseases.
- 2027 sales guidance: $200 million
- 2028 sales guidance: $300 million
- Compound annual growth rate: ~40% through 2028
Plasma Supply Chain as Core Growth Engine
A pivotal move was Green Cross's acquisition of ABO Holdings last year, securing a reliable plasma supply chain essential for IVIG production. The company aims to boost its plasma self-procurement ratio to 80% by 2028, mitigating supply vulnerabilities that plague the industry. Alyglo's differentiated competitiveness—higher potency and stability—further strengthens its edge in a market where U.S. prescriptions are surging due to improved diagnostics and awareness of plasma-derived therapies.
Financial Upside and Strategic Portfolio Expansion
Heungkuk Securities forecasts Alyglo contributing 250 billion won to Green Cross's 2025 revenue of 2.25 trillion won and 52% of its 96.1 billion won operating profit. By 2028, operating margins could hit 30%, driven by scale and efficiency. Broader momentum includes turnarounds at subsidiaries like GC Cell and upcoming subcutaneous immunoglobulin (SCIG) development, enhancing value in a biopharma landscape shifting toward self-sufficient supply chains and diversified immunotherapies.
The firm maintains a "Buy" rating with a 190,000 won target price, signaling confidence in Alyglo's role amid U.S. healthcare trends favoring high-margin biologics for chronic care.
